Differentiation of dopamine agonists and their role in the treatment of Parkinson's disease.
Identifieur interne : 000026 ( Ncbi/Merge ); précédent : 000025; suivant : 000027Differentiation of dopamine agonists and their role in the treatment of Parkinson's disease.
Auteurs : D B Calne [Canada]Source :
- Journal of neural transmission. Supplementum [ 0303-6995 ] ; 1999.
English descriptors
- KwdEn :
- MESH :
- chemical , chemistry : Receptors, Dopamine.
- chemical , drug effects : Receptors, Dopamine.
- chemical , therapeutic use : Antiparkinson Agents, Dopamine Agonists.
- drug therapy : Parkinson Disease.
- Amino Acid Sequence, Humans, Molecular Sequence Data.
Abstract
Since the pioneering work of Hornykiewicz and his colleagues, it has been recognized that dopaminergic cells die selectively in Parkinson's disease, and considerable improvement in symptoms can be achieved by administering levodopa, so that it may be converted to dopamine. However, levodopa has side-effects, and its duration of action is relatively brief. For these reasons, alternative approaches have been undertaken to stimulate the dopamine receptors. In particular, artificial agonists for dopamine receptors have been developed. The pioneer compound was bromocriptine, which stimulates the D2 family of receptors. Bromocriptine is an ergot derivative, and other compounds that are structurally related to ergot have been developed. In particular, lisuride and pergolide have been used for several years. Recently, an ergot derivative with an exceptionally long plasma half-life has been studied, cabergoline. Now there are also non-ergot derivatives that are D2 agonists, and are likely to have a role in the treatment of Parkinson's disease. Both ropinirole and pramipexole fall into this category, and each has been released in various countries for the treatment of Parkinson's disease. All of these compounds stimulate the D2 family of receptors, but they have varying actions on the D1 family of receptors. At present, there is no definite information on the role of the D1 family of receptors in either the therapeutic response to levodopa, or the development of adverse reactions. However, preliminary studies with a D1 agonist, ABT-431, are now in progress.
PubMed: 10370912
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001736
- to stream PubMed, to step Curation: 001736
- to stream PubMed, to step Checkpoint: 001736
Links to Exploration step
pubmed:10370912Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Differentiation of dopamine agonists and their role in the treatment of Parkinson's disease.</title><author><name sortKey="Calne, D B" sort="Calne, D B" uniqKey="Calne D" first="D B" last="Calne">D B Calne</name><affiliation wicri:level="1"><nlm:affiliation>Vancouver Hospital and Health Sciences Centre, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Vancouver Hospital and Health Sciences Centre</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1999">1999</date><idno type="RBID">pubmed:10370912</idno><idno type="pmid">10370912</idno><idno type="wicri:Area/PubMed/Corpus">001736</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001736</idno><idno type="wicri:Area/PubMed/Curation">001736</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001736</idno><idno type="wicri:Area/PubMed/Checkpoint">001736</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001736</idno><idno type="wicri:Area/Ncbi/Merge">000026</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Differentiation of dopamine agonists and their role in the treatment of Parkinson's disease.</title><author><name sortKey="Calne, D B" sort="Calne, D B" uniqKey="Calne D" first="D B" last="Calne">D B Calne</name><affiliation wicri:level="1"><nlm:affiliation>Vancouver Hospital and Health Sciences Centre, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Vancouver Hospital and Health Sciences Centre</wicri:regionArea></affiliation></author></analytic><series><title level="j">Journal of neural transmission. Supplementum</title><idno type="ISSN">0303-6995</idno><imprint><date when="1999" type="published">1999</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amino Acid Sequence</term><term>Antiparkinson Agents (therapeutic use)</term><term>Dopamine Agonists (therapeutic use)</term><term>Humans</term><term>Molecular Sequence Data</term><term>Parkinson Disease (drug therapy)</term><term>Receptors, Dopamine (chemistry)</term><term>Receptors, Dopamine (drug effects)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Receptors, Dopamine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Receptors, Dopamine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Dopamine Agonists</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Amino Acid Sequence</term><term>Humans</term><term>Molecular Sequence Data</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Since the pioneering work of Hornykiewicz and his colleagues, it has been recognized that dopaminergic cells die selectively in Parkinson's disease, and considerable improvement in symptoms can be achieved by administering levodopa, so that it may be converted to dopamine. However, levodopa has side-effects, and its duration of action is relatively brief. For these reasons, alternative approaches have been undertaken to stimulate the dopamine receptors. In particular, artificial agonists for dopamine receptors have been developed. The pioneer compound was bromocriptine, which stimulates the D2 family of receptors. Bromocriptine is an ergot derivative, and other compounds that are structurally related to ergot have been developed. In particular, lisuride and pergolide have been used for several years. Recently, an ergot derivative with an exceptionally long plasma half-life has been studied, cabergoline. Now there are also non-ergot derivatives that are D2 agonists, and are likely to have a role in the treatment of Parkinson's disease. Both ropinirole and pramipexole fall into this category, and each has been released in various countries for the treatment of Parkinson's disease. All of these compounds stimulate the D2 family of receptors, but they have varying actions on the D1 family of receptors. At present, there is no definite information on the role of the D1 family of receptors in either the therapeutic response to levodopa, or the development of adverse reactions. However, preliminary studies with a D1 agonist, ABT-431, are now in progress.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10370912</PMID><DateCreated><Year>1999</Year><Month>08</Month><Day>02</Day></DateCreated><DateCompleted><Year>1999</Year><Month>08</Month><Day>02</Day></DateCompleted><DateRevised><Year>2005</Year><Month>11</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0303-6995</ISSN><JournalIssue CitedMedium="Print"><Volume>56</Volume><PubDate><Year>1999</Year></PubDate></JournalIssue><Title>Journal of neural transmission. Supplementum</Title><ISOAbbreviation>J. Neural Transm. Suppl.</ISOAbbreviation></Journal><ArticleTitle>Differentiation of dopamine agonists and their role in the treatment of Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>185-92</MedlinePgn></Pagination><Abstract><AbstractText>Since the pioneering work of Hornykiewicz and his colleagues, it has been recognized that dopaminergic cells die selectively in Parkinson's disease, and considerable improvement in symptoms can be achieved by administering levodopa, so that it may be converted to dopamine. However, levodopa has side-effects, and its duration of action is relatively brief. For these reasons, alternative approaches have been undertaken to stimulate the dopamine receptors. In particular, artificial agonists for dopamine receptors have been developed. The pioneer compound was bromocriptine, which stimulates the D2 family of receptors. Bromocriptine is an ergot derivative, and other compounds that are structurally related to ergot have been developed. In particular, lisuride and pergolide have been used for several years. Recently, an ergot derivative with an exceptionally long plasma half-life has been studied, cabergoline. Now there are also non-ergot derivatives that are D2 agonists, and are likely to have a role in the treatment of Parkinson's disease. Both ropinirole and pramipexole fall into this category, and each has been released in various countries for the treatment of Parkinson's disease. All of these compounds stimulate the D2 family of receptors, but they have varying actions on the D1 family of receptors. At present, there is no definite information on the role of the D1 family of receptors in either the therapeutic response to levodopa, or the development of adverse reactions. However, preliminary studies with a D1 agonist, ABT-431, are now in progress.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Calne</LastName><ForeName>D B</ForeName><Initials>DB</Initials><AffiliationInfo><Affiliation>Vancouver Hospital and Health Sciences Centre, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Austria</Country><MedlineTA>J Neural Transm Suppl</MedlineTA><NlmUniqueID>0425126</NlmUniqueID><ISSNLinking>0303-6995</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018491">Dopamine Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011954">Receptors, Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018491" MajorTopicYN="N">Dopamine Agonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011954" MajorTopicYN="N">Receptors, Dopamine</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>20</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>6</Month><Day>17</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>6</Month><Day>17</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10370912</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Canada</li></country></list><tree><country name="Canada"><noRegion><name sortKey="Calne, D B" sort="Calne, D B" uniqKey="Calne D" first="D B" last="Calne">D B Calne</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000026 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000026 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:10370912
|texte= Differentiation of dopamine agonists and their role in the treatment of Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:10370912" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |